{"status":"ok","message-type":"work-list","message-version":"1.0.0","message":{"facets":{},"total-results":170384,"items":[{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T14:29:05Z","timestamp":1756996145839},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1986,6]]},"abstract":" Eleven patients with Philadelphia chromosome (Ph1)-positive chronic myelogenous leukemia (CML) in blast crisis (ten patients) or accelerated disease (one patient) were treated with piperazinedione (PIP) and fractionated total body irradiation (TBI) followed by autologous bone marrow transplantation (ABMT). Three patients were transplanted with marrow from which the Ph1 clone had been eradicated by prior intensive chemotherapy. All patients responded with disappearance of blasts in bone marrow and peripheral blood. Six patients achieved a second chronic phase lasting 3 to 14 months (median, 6 months). Two patients had incomplete recovery, and three patients failed to engraft and died from infection. Transplantation with Ph1-negative bone marrow did not improve response duration or survival. Recurrence of blast crisis and incomplete engraftment continue to be the two major problems in this patient group, and more active regimens need to be investigated. <\/jats:p>","DOI":"10.1200\/jco.1986.4.6.906","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T13:23:03Z","timestamp":1487856183000},"page":"906-911","source":"Crossref","is-referenced-by-count":8,"title":["Piperazinedione, total body irradiation, and autologous bone marrow transplantation in chronic myelogenous leukemia."],"prefix":"10.1200","volume":"4","author":[{"given":"L","family":"Vellekoop","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A R","family":"Zander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H M","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J P","family":"Hester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Trujillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K B","family":"McCredie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Zagars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K A","family":"Dicke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1986.4.6.906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T22:35:17Z","timestamp":1653518117000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1986.4.6.906"}},"issued":{"date-parts":[[1986,6]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1986,6]]}},"alternative-id":["10.1200\/JCO.1986.4.6.906"],"URL":"https:\/\/doi.org\/10.1200\/jco.1986.4.6.906","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[1986,6]]}},{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T08:26:39Z","timestamp":1715934399147},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4_suppl","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2016,2,1]]},"abstract":" 25 <\/jats:p> Background: The optimal sequence of endoscopic ultrasonography (EUS) and positron emission tomography with computed tomography (PET\/CT) in esophageal cancer (EC) is a matter of debate. The use of EUS with fine needle aspiration (FNA) after PET\/CT seems to increase the efficacy of curative intended neoadjuvant or definitive chemoradiotherapy. Retrospectively, we assessed the impact of EUS in the PET\/CT upfront model on the treatment decision making in EC patients. Methods: In the period 2009 to 2015, 298 EC patients were staged with hybrid PET\/CT or PET with CT, and EUS if applicable, in a non-specific order to assess curability (T1-4a,N0-3M0). We determined the feasibility of EUS and whether the initial or additional EUS changed the primary decision suspicious incurable (T4b and M+) into curable disease or added extra nodal information leading to up\/downstaging or exhibit suspected nodes at different lymph node stations. In addition, we assessed if EUS changed the radiation area (i.e. lymph nodes > 3.5 cm from the defined radiation target volumes) in the PET\/CT \u201cupfront model\u201d. Results: EUS was complete in 185 (62.1%) and incomplete due to stricture from a relative obstructing tumor in 59 (19.8%) patients. Fifty-four patients (18.1%) did not receive EUS because of stenosis (n = 46; 15.4%), patient dependent reasons (n = 4; 1.3%) or other reasons (n = 4; 1.3%). EUS after hybrid PET\/CT or PET with CT (n = 244) gave additional information in 166 patients (68.0%); it changed the curability in 4 (1.6%), lead to nodal up and downstaging in respectively, 81 (33.2%) and 27 (11.1%) patients, changed the number of or lymph node station of suspected lymph nodes in an additional 58 patients (n = 23.8%), and FNA gave additional information in 34 (13.9%) patients. EUS after PET\/CT \u201dupfront\u201d changed the treatment plan in 90 patients (36.9%), including alteration in the radiation field (86; 35.2%) and curability (4; 1.6%). Conclusions: EUS gave additional information after PET\/CT \u201cup front\u201d and altered the radiation field in about one third of the EC patients, suggesting a better yield of \u201cEUS on indication\u201d after PET\/CT upfront. <\/jats:p>","DOI":"10.1200\/jco.2016.34.4_suppl.25","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T11:01:35Z","timestamp":1487934095000},"page":"25-25","update-policy":"http:\/\/dx.doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["The value of endoscopic ultrasonography in a PET\/CT upfront model in staging esophageal cancer with respect to treatment decision."],"prefix":"10.1200","volume":"34","author":[{"given":"Jan-Binne","family":"Hulshoff","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiske E.M.","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Noordzij","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter B.","family":"Nagengast","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik M.","family":"van Dullemen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique E.M.","family":"Mul","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Theodorus","family":"Plukker","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","link":[{"URL":"http:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/jco.2016.34.4_suppl.25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T08:56:23Z","timestamp":1653814583000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/jco.2016.34.4_suppl.25"}},"issued":{"date-parts":[[2016,2,1]]},"references-count":0,"journal-issue":{"issue":"4_suppl","published-print":{"date-parts":[[2016,2,1]]}},"alternative-id":["10.1200\/jco.2016.34.4_suppl.25"],"URL":"https:\/\/doi.org\/10.1200\/jco.2016.34.4_suppl.25","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2016,2,1]]},"assertion":[{"value":"2016-02-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]},{"indexed":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T04:44:20Z","timestamp":1678855460472},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6_suppl","funder":[{"name":"None."}],"content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2023,2,20]]},"abstract":" 633 <\/jats:p> Background: The treatment landscape of advanced renal cell carcinoma (RCC) drastically changed with the approval of tyrosine kinase inhibitors (TKIs). Since then, immunotherapy (IO) and now TKI plus IO combination therapies is considered standard-of-care. Despite multiple drug approvals, it remains unclear how much improvement in survival these therapies have provided. Methods: We reviewed the US Food and Drug Administration (FDA) website to evaluate all approvals for RCC from 2005 to 2022. We collected progression-free survival (PFS) and overall survival (OS) from the approval notification or from the corresponding clinical trial cited for drug approval. Results: Between 2005 and 2022, there were 16 drug (single or combination) approvals for advanced RCC. Most therapy approvals (93.75%) were granted through accelerated approval. Eight approvals were TKIs, 6 approvals were TKI plus IO combination therapies, and 1 approval each were for immunotherapy and a VEGF inhibitor. Average PFS benefit for 1st<\/jats:sup> line approvals was 5.63 months (range 1.9-14.7) and average PFS benefit for 2nd<\/jats:sup> or later line approvals was 2.95 months (range 0.2-9.1). Average OS benefit in the 1st<\/jats:sup> line setting was 3.6 months and average OS benefit in the 2nd<\/jats:sup> or later line setting was 5.4 months. Conclusions: Despite 16 drug (single or combination) approvals for advanced RCC since 2005, the improvements in average PFS and OS were modest. As OS data matures from recent TKI plus IO combination therapies, OS benefit may improve. Nonetheless, continued drug development is urgently warranted in advanced RCC. [Table: see text] <\/jats:p>","DOI":"10.1200\/jco.2023.41.6_suppl.633","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T15:22:32Z","timestamp":1678807352000},"page":"633-633","update-policy":"http:\/\/dx.doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Characterization and survival benefit of drugs approved for advanced renal cell carcinoma."],"prefix":"10.1200","volume":"41","author":[{"given":"David Joseph","family":"Benjamin","sequence":"first","affiliation":[{"name":"Hoag Family Cancer Institute, Newport Beach, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash","family":"Rezazadeh","sequence":"additional","affiliation":[{"name":"University of California Irvine Medical Center, Orange, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2023.41.6_suppl.633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T21:12:13Z","timestamp":1678828333000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2023.41.6_suppl.633"}},"issued":{"date-parts":[[2023,2,20]]},"references-count":0,"journal-issue":{"issue":"6_suppl","published-print":{"date-parts":[[2023,2,20]]}},"alternative-id":["10.1200\/JCO.2023.41.6_suppl.633"],"URL":"https:\/\/doi.org\/10.1200\/jco.2023.41.6_suppl.633","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2023,2,20]]},"assertion":[{"value":"2023-02-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]},{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T11:12:11Z","timestamp":1648984331403},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"18_suppl","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2007,6,20]]},"abstract":" 9058 <\/jats:p> Background: Secondary - potentially reversible - causes of cancer-related anorexia, a common and devastating complication of advanced cancer, remain poorly recognised in daily practice. To explore the frequency of SecAn and evaluate the practice- guiding-potential (PGP) of a novel clinical assessment checklist (CL-SecAn). Methods: The 11 item CL-SecAn is based on literature review and multiprofessional clinical expert opinions. Patients rate the answers to the questions \u201cI feel anorectic because of [i.e. stomatitis]\u201d by an 1\u20134 categorical scale (no, little, moderate, a lot). Consecutive patients of an interdisciplinary palliative-oncological outpatient \u201cnutrition & fatigue\u201d clinic (NF-clinic) and of a multicenter cross-sectional advanced cancer pain study completed the CL-SecAn. Charts of the NF-clinic were retrospectively reviewed for onset or change of therapeutic interventions (Tx-SecAn) focused on identified causes of SecAn. Patients with (rating 3 or 4) or without (1 or 2) one of the 11 SecAn causes were compared to estimate PGP. In addition, matched (age, sex, tumor, cachexia) \u201cregular\u201d out-patients are compared to NF-clinic patients for Tx-SecAn. Results: SecAn was present (defined as =3\/4) in 63 of 113 (56%) patients (53 NF-clinic, 60 study; f:m 45:68; age 64 [median, range 25, 88]; 30% gastrointestinal, 20% lung, 13% prostate, 10% urogenital, and 17% other cancer, 10% lymphoma). SecAn causes were: stomatitis 4%, dysgeusia 19%, dysphagia 8%, epigastric pain 9%, abdominal pain 14%, constipation19%, diarrhea 5%, defecation after a meal 2%, pain 12%, dyspnoea 3% and fatigue 13%. In 36 (32%) patients more than one cause was present. Tx-SecAn for dysgeusia was applied in 7 of 15 patients (46%) with and 3 of 38 (8%) without Sec-An Dysgeusia. For constipation, Tx-SecAn was modified in 70% with and 27% without Sec-An constipation. The other 9 Sec-An were analysed accordingly. The case-control study is currently ongoing. Conclusions: SecAn causes seem to be common in advanced cancer patients. The CL-SecAn carries a Practice-Guiding-Potential, at least for some of the 11 SecAn causes, its potential might be underrecognized in frequently treated syndromes, such as constipation. Future research will investigate further the impact of CL-SecAn. <\/jats:p> No significant financial relationships to disclose. <\/jats:p>","DOI":"10.1200\/jco.2007.25.18_suppl.9058","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T20:57:34Z","timestamp":1583528254000},"page":"9058-9058","source":"Crossref","is-referenced-by-count":1,"title":["Secondary causes of cancer-related anorexia: Recognition in daily practice by a novel checklist, a pilot study"],"prefix":"10.1200","volume":"25","author":[{"given":"A. G.","family":"Omlin","sequence":"first","affiliation":[{"name":"Cantonal Hospital, St.Gallen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Strasser","sequence":"additional","affiliation":[{"name":"Cantonal Hospital, St.Gallen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","deposited":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T21:03:21Z","timestamp":1583528601000},"score":0.0,"resource":{"primary":{"URL":"http:\/\/ascopubs.org\/doi\/10.1200\/jco.2007.25.18_suppl.9058"}},"issued":{"date-parts":[[2007,6,20]]},"references-count":0,"journal-issue":{"issue":"18_suppl","published-print":{"date-parts":[[2007,6,20]]}},"alternative-id":["10.1200\/jco.2007.25.18_suppl.9058"],"URL":"https:\/\/doi.org\/10.1200\/jco.2007.25.18_suppl.9058","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2007,6,20]]}},{"indexed":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:25:47Z","timestamp":1717460747038},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"16_suppl","funder":[{"name":"None."}],"content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2024,6,1]]},"abstract":" e23104 <\/jats:p> Background: Registrational clinical trials have led to the FDA approval of numerous immunotherapy (IO) agents in the treatment of non-small cell lung cancer (NSCLC) since 2015. Given the historical lack of adequate representation of the US population with cancer in clinical trials, we aimed to analyze disparities in race and ethnicity reporting and enrollment in lung cancer clinical trials that led to FDA-approved immunotherapies between 2015-2023. Methods: The FDA archives and database were queried to review all FDA drug approvals for IO approved to treat NSCLC between 2015 to 2023. Enrollment data were obtained from FDA labels, ClinicalTrials.gov, and corresponding journal manuscripts. The enrollment incidence ratio (EIR) and enrollment mortality ratio (EMR) were calculated as the proportion of patients of a particular race among clinical trial participants in approval studies divided by the estimated proportion of patients of that particular race diagnosed or dying of lung cancer, respectively, among the US population. Results: Among 27 trials with a total of 15,878 subjects, distribution by race shows that 77.5% were White, 16.7% Asian, 8.8% Hispanic, 1.63% Black, 0.33% American Indian Alaska Native (AIAN), and 0.07% were Native Hawaiian and Other Pacific Islander (NHOPI). 67.4% were males while 32.6% were females. The EIR for Non-Hispanic White, Non-Hispanic Black, Asian, and Hispanic patients was 0.99, 0.13, 3.56, and 0.85 respectively. The EMR for Non-Hispanic White, Non-Hispanic Black, Asian, and Hispanic patients was 0.99, 0.12, 4.23, and 0.96 respectively. Racial demographics were reported in 65% of journal manuscripts, 65% of ClinicalTrials.gov pages, and 92% of FDA labels while ethnicity demographics were reported in 0% of journal manuscripts, 42% of ClinicalTrials.gov pages, and 15% of FDA labels. Conclusions: Black, AIAN and female patients are severely underrepresented in lung cancer trials that lead to approval for IO based therapy. Asian patients were overrepresented. Less than half of the trials reported data on ethnicity. Further research is needed to see if regulatory initiatives to increase clinical trial diversity result in more equitable clinical trial enrollment in pivotal trials. <\/jats:p>","DOI":"10.1200\/jco.2024.42.16_suppl.e23104","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T20:56:51Z","timestamp":1717448211000},"page":"e23104-e23104","update-policy":"http:\/\/dx.doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Investigating disparities in enrollment of patients in lung cancer clinical trials that led to FDA approval for immunotherapies between 2015 and 2023: A comparison with the US population."],"prefix":"10.1200","volume":"42","author":[{"given":"Nhu Tuyet","family":"Le","sequence":"first","affiliation":[{"name":"Drexel University College of Medicine, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan Huu-Tuan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"University of Illinois College of Medicine, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2024.42.16_suppl.e23104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T20:57:26Z","timestamp":1717448246000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2024.42.16_suppl.e23104"}},"issued":{"date-parts":[[2024,6,1]]},"references-count":0,"journal-issue":{"issue":"16_suppl","published-print":{"date-parts":[[2024,6,1]]}},"alternative-id":["10.1200\/JCO.2024.42.16_suppl.e23104"],"URL":"https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.e23104","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2024,6,1]]},"assertion":[{"value":"2024-05-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]},{"indexed":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:24:24Z","timestamp":1717460664530},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"16_suppl","funder":[{"name":"None."}],"content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2024,6,1]]},"abstract":" e23258 <\/jats:p> Background: Esophageal cancer (EC) is the sixth leading cause of cancer-related deaths in the United States, with a mere 20% survival rate in the first five years, making it a significant public health concern. Considering the lack of comprehensive evaluations of mortality trends that are undergoing substantial transformations on a global scale, this study aims to provide an update on the mortality rates of esophageal cancer and its trends in the United States. Methods: The mortality trends among adults with EC were analyzed using data from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiological Research (CDC WONDER) database, where EC was presented as a contributing or the underlying cause of death. Code C15 \u201cMalignant Neoplasms of Esophagus\u201d in the International Classification of Disease, tenth revision (ICD-10) was used to identify the data. Crude and age-adjusted mortality rates (AAMRs) per 100,000 people were extracted. Annual percent changes (APCs) in AAMRs with 95% CI were obtained using joint point regression analysis across different demographic (sex, race\/ethnicity, and age) and geographic (state, urban-rural, and regional) subgroups. Results: Between 1999 and 2020, 309,725 documented deaths were attributed to esophageal cancer. The overall AAMR decreased from 1999-2020 (6.69 to 5.68). Males had higher consistently higher AAMRs than females (10.96 vs. 2.24). NH White had the highest overall AAMR (6.88), followed by NH Black (6.46), NH American Indian (4.95), Hispanic or Latino (3.31), and NH Asian or Pacific Islander (2.57). CMRs also increased with advancing age and were greatest in individuals over the age of 85 years. AAMR also varied by region (overall AAMR: Midwest: 7.18; Northeast: 6.75; South: 6.07; West: 5.76), and non-metropolitan areas had higher AAMR (non-core areas: 7.09; micropolitan areas: 7.19) than metropolitan areas (large central metropolitan areas: 5.75; large fringe areas: 6.33). The states in the upper 90th percentile of esophageal cancer-related AAMR were Vermont, District of Columbia, West Virginia, Ohio, New Hampshire, and Maine, and exhibited an approximately two-fold increase in AAMRs, compared to states falling in the lower 10th percentile. Conclusions: Over the last two decades, there has been an overall decline in mortality related to EC in the United States. However, demographic and geographic discrepancies in EC-related mortality persist, necessitating additional exploration and development of specifically directed treatments. <\/jats:p>","DOI":"10.1200\/jco.2024.42.16_suppl.e23258","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T21:01:26Z","timestamp":1717448486000},"page":"e23258-e23258","update-policy":"http:\/\/dx.doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Esophageal cancer in the United States: A 21-year mortality analysis (1999-2020)."],"prefix":"10.1200","volume":"42","author":[{"given":"Muhammad Zain","family":"Farooq","sequence":"first","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usama","family":"Kamal","sequence":"additional","affiliation":[{"name":"Services Institute of Medical Sciences, Lahore, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeena","family":"Jamil","sequence":"additional","affiliation":[{"name":"Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eeshal","family":"Fatima","sequence":"additional","affiliation":[{"name":"Services Institute of Medical Sciences, Lahore, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abiha","family":"Khurram","sequence":"additional","affiliation":[{"name":"Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoha","family":"Khan","sequence":"additional","affiliation":[{"name":"Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab","family":"Kamdi","sequence":"additional","affiliation":[{"name":"Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sana","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Vishal","family":"Jaglal","sequence":"additional","affiliation":[{"name":"MCC Physicians, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2024.42.16_suppl.e23258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T21:02:46Z","timestamp":1717448566000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2024.42.16_suppl.e23258"}},"issued":{"date-parts":[[2024,6,1]]},"references-count":0,"journal-issue":{"issue":"16_suppl","published-print":{"date-parts":[[2024,6,1]]}},"alternative-id":["10.1200\/JCO.2024.42.16_suppl.e23258"],"URL":"https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.e23258","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2024,6,1]]},"assertion":[{"value":"2024-05-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]},{"indexed":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T13:21:37Z","timestamp":1720012897925},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"15_suppl","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2013,5,20]]},"abstract":" 635 <\/jats:p> Background: About a third of HER2-overexpressing (HER2+) breast cancer pts will develop brain metastases in the course of their disease. Drug access to normal brain and brain metastases is therefore key to prevention and treatment of cerebral metastases. To provide direct evidence of Lap drug access and evaluate whether therapeutic doses of Lap act as a substrate for efflux transporters, thereby increasing Lap concentrations, we performed positron emission tomography (PET) studies with [11<\/jats:sup>C]Lap. Methods: Pts with HER2+ MBC with an ECOG of <3 were grouped into 2 cohorts: with at least one 1-cm diameter brain metastasis or without brain metastases and underwent 90-minute dynamic cranial PET-CT scans after IV administration of a microdose (<1 mg) of [11<\/jats:sup>C]Lap before and after 8 days of oral Lap (1500 mg once daily). Arterial blood samples were performed to assess [11<\/jats:sup>C]Lap radioactivity contribution in blood and plasma, and the fraction of plasma [11<\/jats:sup>C] radioactivity corresponding to metabolites. Tissue time-radioactivity curves (TACs) were generated and [11<\/jats:sup>C]Lap exposure (AUC; area under TAC) derived for normal brain and brain metastases. Signal dissection of the total image activity was performed to remove the contribution of blood volume to the image and the actual tissue contribution due to [11<\/jats:sup>C]Lap obtained. Results: 6 pts (3 with brain metastasis) were recruited. Arterial plasma analysis revealed that [11<\/jats:sup>C]Lap contributed to >80% of activity in plasma at 60 minutes. Tissue data revealed [11<\/jats:sup>C]Lap signal in normal brain was low with no appreciable uptake observed when corrected for blood volume contribution. [11<\/jats:sup>C]Lap uptake was higher in brain metastases compared with normal brain and appreciable, even after correction for tissue blood volume contribution. Uptake was also observed in extra-cranial normal tissue. There was no difference in [11<\/jats:sup>C]Lap uptake in normal brain and metastases between treatment-na\u00efve and post-treatment scans. Conclusions: [11<\/jats:sup>C]Lap uptake in brain metastases was higher than in normal brain. [11<\/jats:sup>C]Lap drug access to brain metastases might therefore indicate possible efficacy against HER2+ brain metastases. Clinical trial information: NCT01290354. <\/jats:p>","DOI":"10.1200\/jco.2013.31.15_suppl.635","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T19:26:33Z","timestamp":1583954793000},"page":"635-635","source":"Crossref","is-referenced-by-count":4,"title":["Brain and tumor penetration of carbon-11\u2013labeled lapatinib ([11<\/sup>C]Lap) in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC)."],"prefix":"10.1200","volume":"31","author":[{"given":"Azeem","family":"Saleem","sequence":"first","affiliation":[{"name":"Imanova Centre for Imaging Sciences, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Searle","sequence":"additional","affiliation":[{"name":"Imanova Centre for Imaging Sciences, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M.","family":"Kenny","sequence":"additional","affiliation":[{"name":"Imperial College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mickael","family":"Huiban","sequence":"additional","affiliation":[{"name":"Imanova Centre for Imaging Sciences, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Waldman","sequence":"additional","affiliation":[{"name":"Department of Imaging, Imperial College, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Downie","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Uxbridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Lau","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Oncology, Uxbridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip S","family":"Murphy","sequence":"additional","affiliation":[{"name":"philip.s.murphy@gsk.com, Uxbridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasia","family":"Kozlowski","sequence":"additional","affiliation":[{"name":"Imperial College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Lewis","sequence":"additional","affiliation":[{"name":"Imanova Centre for Imaging Sciences, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Woodley","sequence":"additional","affiliation":[{"name":"Charing Cross Hospital, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Hill","sequence":"additional","affiliation":[{"name":"Imanova Centre for Imaging Sciences, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aruloly","family":"Kamalakaran","sequence":"additional","affiliation":[{"name":"Imanova Centre for Imaging Sciences, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Hirschberg","sequence":"additional","affiliation":[{"name":"Niche Science & Technology, Twickenham, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Kaneko","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Uxbridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Aboagye","sequence":"additional","affiliation":[{"name":"Imperial College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Marini","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Charles","family":"Coombes","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","deposited":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T19:26:55Z","timestamp":1583954815000},"score":0.0,"resource":{"primary":{"URL":"http:\/\/ascopubs.org\/doi\/10.1200\/jco.2013.31.15_suppl.635"}},"issued":{"date-parts":[[2013,5,20]]},"references-count":0,"journal-issue":{"issue":"15_suppl","published-print":{"date-parts":[[2013,5,20]]}},"alternative-id":["10.1200\/jco.2013.31.15_suppl.635"],"URL":"https:\/\/doi.org\/10.1200\/jco.2013.31.15_suppl.635","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2013,5,20]]}},{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T02:22:10Z","timestamp":1648779730400},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"15_suppl","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2017,5,20]]},"abstract":" e15676 <\/jats:p> Background: The prognosis for patients (pts) with advanced hepatocellular carcinoma (HCC) after failure of sorafenib is poor, with few systemic therapy options. c-Met is a receptor tyrosine kinase implicated in the progression of HCC. Tepotinib, a highly selective c-Met inhibitor, has shown activity first-line in patients with c-Met+ HCC. We report final results of a phase Ib study of tepotinib in pts with advanced HCC after failure of first-line sorafenib. Methods: Eligible pts were \u226518 years with advanced HCC, Child-Pugh Class A, ECOG PS 0-1, and progression after \u22654 weeks of sorafenib. Tepotinib doses of 300 and 500 mg\/day on a 21-day cycle were explored to establish the recommended phase II dose (RP2D) of tepotinib. Secondary objectives included antitumor activity by RECIST v1.1, biochemical response, and safety. Results: Seventeen pts were enrolled: 4 pts received tepotinib 300 mg\/day and 13 pts 500 mg\/day, confirmed as the RP2D. Fourteen pts experienced treatment-related adverse events (TRAEs), the most frequent being peripheral edema (n = 5, 2 grade 3), lipase increase (2, 1 grade 3), acute kidney injury (2, 1 grade 3), renal impairment (2, 1 grade 3), fatigue (2), nausea (2), asthenia (2). One pt with peripheral edema permanently discontinued treatment. No grade \u22654 TRAEs and no dose-limiting toxicities (DLTs) were reported. The best overall response was partial response (PR) in 2 pts and stable disease (SD) in 4 pts. The duration of the PRs was 57 and 91 weeks. In the first of these pts, tumor size decreased by 55% and serum alfa-fetoprotein (AFP) levels had decreased from 15,923 \u03bcg\/L at baseline to < 3,000 \u03bcg\/L by day 15 of cycle 2 and remained at this level until progression. In the second pt, tumor size decreased by > 60% from baseline. No consistent change in AFP was seen in pts with SD. Median overall survival was 7.2 months (range 0.7\u201322.9 months). Conclusions: The RP2D of tepotinib as second-line therapy for pts with advanced HCC who progress after sorafenib treatment is 500 mg\/day. Tepotinib was well tolerated at this dose and showed signs of activity. The ongoing phase II part of this trial is investigating the efficacy and safety of tepotinib 500 mg\/day in pts with c-Met+ HCC. Clinical trial information: NCT02115373. <\/jats:p>","DOI":"10.1200\/jco.2017.35.15_suppl.e15676","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T15:44:30Z","timestamp":1536248670000},"page":"e15676-e15676","source":"Crossref","is-referenced-by-count":2,"title":["Final phase Ib data for the oral c-Met inhibitor tepotinib in patients with previously treated advanced hepatocellular carcinoma."],"prefix":"10.1200","volume":"35","author":[{"given":"Sandrine J.","family":"Faivre","sequence":"first","affiliation":[{"name":"Oncology Unit, Beaujon University Hospital, Clichy, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Blanc","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9pato-Gastroent\u00e9rologie et d\u2019Oncologie Digestive, Groupe Hospitalier Saint Andr\u00e9, Bordeaux, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Merle","sequence":"additional","affiliation":[{"name":"Service d'Hepatogastroent\u00e9rologie, H\u00f4pital de la Croix Rousse, Lyon, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Fasolo","sequence":"additional","affiliation":[{"name":"San Raffaele Scientific Institute, Milan, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Iacobellis","sequence":"additional","affiliation":[{"name":"Ospedale Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Decaens","sequence":"additional","affiliation":[{"name":"Service d'Hepatogastroent\u00e9rologie, CHU de Grenoble - H\u00f4pital Nord, Grenoble, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Villa","sequence":"additional","affiliation":[{"name":"Policlinico di Modena, Modena, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorg","family":"Trojan","sequence":"additional","affiliation":[{"name":"Goethe University Hospital and Cancer Center, Frankfurt, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Grando","sequence":"additional","affiliation":[{"name":"H\u00f4pital Jean-Verdier, Bondy, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Ellers-Lenz","sequence":"additional","affiliation":[{"name":"Merck KGaA, Darmstadt, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Zhao","sequence":"additional","affiliation":[{"name":"EMD Serono, Inc., Billerica, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Raymond","sequence":"additional","affiliation":[{"name":"Oncology Unit, Beaujon University Hospital, Clichy, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","link":[{"URL":"http:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2017.35.15_suppl.e15676","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T20:02:37Z","timestamp":1584043357000},"score":0.0,"resource":{"primary":{"URL":"http:\/\/ascopubs.org\/doi\/10.1200\/JCO.2017.35.15_suppl.e15676"}},"issued":{"date-parts":[[2017,5,20]]},"references-count":0,"journal-issue":{"issue":"15_suppl","published-print":{"date-parts":[[2017,5,20]]}},"alternative-id":["10.1200\/JCO.2017.35.15_suppl.e15676"],"URL":"https:\/\/doi.org\/10.1200\/jco.2017.35.15_suppl.e15676","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2017,5,20]]}},{"indexed":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T04:26:41Z","timestamp":1728016001028},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"16_suppl","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2022,6]]},"abstract":"\n 6031<\/jats:bold>\n <\/jats:p>\n \n Background:<\/jats:bold>\n Patients with cancer have worse outcomes from COVID-19 infection. However, the specific impact of COVID-19 on patients with head and neck cancer (HNC) is largely unknown. The COVID-19 and Cancer Consortium (CCC19) maintains an international registry (NCT04354701) aimed to investigate the clinical course and complications of COVID-19 in patients with cancer. Here, we report severity of COVID-19 and its complications among HNC patients.\n Methods:<\/jats:bold>\n The CCC19 registry was queried for patients with HNC and laboratory confirmed SARS-CoV-2 infection. The co-primary outcomes were severity of COVID-19 illness on an ordinal scale (0: no complications; 1: hospitalized, no oxygen (O2); 2: hospitalized, required O2; 3: ICU admission; 4: mechanical ventilation (MV); 5: death), and severity of complications (mild, moderate, serious). The outcomes were further stratified by demographics, recent treatment (systemic vs local; surgery, radiation (RT) vs systemic), treatment intent (palliative vs curative), and cancer status (remission, responding, stable, progressing).\n Results:<\/jats:bold>\n From March 2020 to December 2021, 356 HNC patients were identified. Median age was 65 (interquartile range 58-74), 29% were female, 56% were white, 67% were former or current smokers, 20% had a BMI >30, 15% had an ECOG performance status >2, and 57% had >2 comorbidities. 154 (43%) had no complications, 61 (17%) were hospitalized without O2, 135 (38%) were hospitalized with O2, 50 (14%) required ICU, 32 (9%) required MV, and 74 (21%) died. 88 (25%) had mild, 59 (17%) had moderate, and 132 (37%) had serious complications. 33% of patients who received systemic therapy and 30% who received RT within 3 mo prior to COVID-19 diagnosis died. Mortality was higher in patients receiving palliative when compared to curative intent treatment (44% vs 16%). In addition, 50% of patients with actively progressing cancer, and 45% who had serious complications died. Importantly, 37 (n=12 palliative systemic therapy and n=25 local therapy) patients had a treatment delay due to COVID-19 diagnosis.\n Conclusions:<\/jats:bold>\n Our study is the largest cohort to date describing COVID-19 outcomes in HNC patients and suggest a high rate of mortality even in those receiving local and curative intent treatment. Variables stratified by COVID-19 severity. Note: Ordinal levels 3 and 4 not shown due to small case numbers.\n \n \n \n \n Characteristics<\/jats:th>\n Worst severity of COVID-19 illness<\/jats:th>\n <\/jats:tr>\n \n 0(N=150)%<\/jats:th>\n 1(N=51)%<\/jats:th>\n 2(N=60)%<\/jats:th>\n 5(N=74)%<\/jats:th>\n <\/jats:tr>\n <\/jats:thead>\n \n \n Complication severityMildModerateSerious<\/jats:td>\n 8425<3<\/jats:td>\n 1037<10<\/jats:td>\n <8278<\/jats:td>\n <7845<\/jats:td>\n <\/jats:tr>\n \n ECOG>2<\/jats:td>\n 15<\/jats:td>\n <10<\/jats:td>\n 19<\/jats:td>\n 52<\/jats:td>\n <\/jats:tr>\n \n Obesity (BMI >30)<\/jats:td>\n 49<\/jats:td>\n 10<\/jats:td>\n 25<\/jats:td>\n 10<\/jats:td>\n <\/jats:tr>\n \n SmokingNeverFormer\/current<\/jats:td>\n 4938<\/jats:td>\n 1216<\/jats:td>\n 1419<\/jats:td>\n 1921<\/jats:td>\n <\/jats:tr>\n \n Treatment intentCurativePalliative<\/jats:td>\n 4825<\/jats:td>\n 1615<\/jats:td>\n 1915<\/jats:td>\n 1644<\/jats:td>\n <\/jats:tr>\n \n Treatment modalitySystemic therapyLocal therapy<\/jats:td>\n 3430<\/jats:td>\n 1910<\/jats:td>\n 1128<\/jats:td>\n 3327<\/jats:td>\n <\/jats:tr>\n \n Cancer statusRemission\/NEDResponding\/stableProgressing<\/jats:td>\n 503925<\/jats:td>\n 121814<\/jats:td>\n 1824<8<\/jats:td>\n 121650<\/jats:td>\n <\/jats:tr>\n <\/jats:tbody>\n <\/jats:table>\n \n Note: Ordinal levels 3 and 4 not shown due to small case number<\/jats:p>\n <\/jats:table-wrap-foot>\n <\/jats:table-wrap>\n <\/jats:p>","DOI":"10.1200\/jco.2022.40.16_suppl.6031","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T19:44:38Z","timestamp":1727984678000},"page":"6031-6031","update-policy":"http:\/\/dx.doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Complications and severity of COVID-19 in patients with head and neck cancer (HNC): A COVID-19 and Cancer Consortium (CCC19) registry analysis."],"prefix":"10.1200","volume":"40","author":[{"given":"Vidhya","family":"Karivedu","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Ohio State University, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Yuan","family":"Hsu","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, TN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Deeken","sequence":"additional","affiliation":[{"name":"Inova Schar Cancer Institute, Fairfax, VA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin R","family":"Jhawar","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel G.","family":"Stover","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel W.","family":"Bowles","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Hwang","sequence":"additional","affiliation":[{"name":"Henry Ford Health System, Detroit, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[{"name":"University of California San Diego Health, La Jolla, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Ruiz-Garcia","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Cancerologia, Mexico City, Mexico;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziad","family":"Bakouny","sequence":"additional","affiliation":[{"name":"Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arielle","family":"Sabbah","sequence":"additional","affiliation":[{"name":"McGill, Montreal, QC, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Klein","sequence":"additional","affiliation":[{"name":"The Warren Alpert Medical School of Brown University and Lifespan Cancer Institute, Providence, RI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Paul","family":"Yu","sequence":"additional","affiliation":[{"name":"Hartford HealthCare Cancer Institute, Hartford, CT;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Glover","sequence":"additional","affiliation":[{"name":"Stanford University Medical Center, Stanford, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wotman","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric B.","family":"Durbin","sequence":"additional","affiliation":[{"name":"Kentucky Cancer Registry, Lexington, KY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"University of Minnesota, Minneapolis, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibel","family":"Blau","sequence":"additional","affiliation":[{"name":"Rainier Hematology Oncology\/Northwest Medical Specialties, Seattle, WA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigrun","family":"Hallmeyer","sequence":"additional","affiliation":[{"name":"Oncology Specialists, SC, Park Ridge, IL;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trisha Michel","family":"Wise-Draper","sequence":"additional","affiliation":[{"name":"University of Cincinnati Cancer Center, Cincinnati, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"COVID-19 and Cancer Consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2022.40.16_suppl.6031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T19:44:40Z","timestamp":1727984680000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2022.40.16_suppl.6031"}},"issued":{"date-parts":[[2022,6]]},"references-count":0,"journal-issue":{"issue":"16_suppl","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1200\/JCO.2022.40.16_suppl.6031"],"URL":"https:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.6031","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"2022-06-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]},{"indexed":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:23:38Z","timestamp":1717460618446},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"16_suppl","funder":[{"DOI":"10.13039\/100000002","name":"U.S. National Institutes of Health","doi-asserted-by":"crossref","award":["T32CA009515"],"award-info":[{"award-number":["T32CA009515"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000801","name":"Bayer Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2024,6,1]]},"abstract":" 11147 <\/jats:p> Background: Real world data describing EOL care in HNSCC is limited. We performed a retrospective study evaluating EOL in HNSCC vs OST in a population-based sample of patients in WA. Methods: We used a database linking WA state cancer registry records with claims records from Medicare, Medicaid, and two large commercial insurers. Patients with HNSCC (oral cavity, oropharynx, hypopharynx, or larynx) were compared to OST (any solid tumor diagnosis). Adults with AJCC stage II-IV or SEER stage Regional\/Distant who died in 2011-2021 with continuous insurance enrollment 6 months before death were included. We compared proportions of patients with >1 ED visits in the last 30 days of life, ICU admission in the last 30 days of life, chemotherapy in the last 14 days of life, and hospice enrollment at least 3 days prior to death. We performed multivariate regression analysis to determine factors associated with hospice enrollment. Results: 1,389 patients with HNSCC and 41,412 patients with OST were identified. Demographics for HNSCC vs OST included median age 68 vs 73, white race 91.5% vs 90.1%, stage IV 57.5% vs 45.3%. Insurance types for HNSCC vs OST were commercial 8.4% vs 9.8%, Medicaid 16.6% vs 8.8%, Medicare 59.1% vs 65.5%, multiple 15.8% vs 15.9% (p<0.0001). HNSCC patients had lower rates of >1 ED visits compared to OST (14.1% vs 16.4%, p=0.02); there was no significant difference in ICU admission (25.1% vs 24.0%, p=0.3) or chemotherapy receipt (6.3% vs 5.1%, p=0.056). Hospice enrollment was significantly lower in HNSCC patients (49.0% vs 56.4%, p<0.0001). A stratified analysis limited to stage IV patients yielded consistent findings in all categories. HNSCC patients died more at home and less in hospice (20.2% vs 12.7% and 41.5% vs 52.0%, p<0.0001). In a multivariate regression analysis (Table) HNSCC, black race, living with a partner, or living in neighborhoods with higher area deprivation index (ADI) was associated with lower hospice enrollment. Patients with Medicare or multiple insurance types were more likely to enroll in hospice; AJCC stage was not significant. Conclusions: In this population-based sample, compared to OST, a greater proportion of HNSCC patients were insured by Medicaid at EOL and were less likely to enroll in hospice prior to death. The reasons driving these observed disparities in hospice enrollment warrant further study to optimize EOL care among patients with HNSCC. [Table: see text] <\/jats:p>","DOI":"10.1200\/jco.2024.42.16_suppl.11147","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T20:29:30Z","timestamp":1717446570000},"page":"11147-11147","update-policy":"http:\/\/dx.doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["End of life (EOL) care in head and neck squamous cell carcinoma (HNSCC) compared to other solid tumors (OST) in Washington (WA) State."],"prefix":"10.1200","volume":"42","author":[{"given":"Lauren","family":"Shih","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Sun","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine R.","family":"Fedorenko","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal D.","family":"Futran","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Barber","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Marchiano","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Upendra","family":"Parvathaneni","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay Justin","family":"Liao","sequence":"additional","affiliation":[{"name":"University of Washington Medical Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina P.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott David","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veena","family":"Shankaran","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2024.42.16_suppl.11147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T20:30:08Z","timestamp":1717446608000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2024.42.16_suppl.11147"}},"issued":{"date-parts":[[2024,6,1]]},"references-count":0,"journal-issue":{"issue":"16_suppl","published-print":{"date-parts":[[2024,6,1]]}},"alternative-id":["10.1200\/JCO.2024.42.16_suppl.11147"],"URL":"https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.11147","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2024,6,1]]},"assertion":[{"value":"2024-05-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]},{"indexed":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T22:35:10Z","timestamp":1722119710069},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"15_suppl","funder":[{"name":"Erasmus MC Grants & Cancer Genomics Netherlands"}],"content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2021,5,20]]},"abstract":" 4523 <\/jats:p> Background: International guidelines for the treatment of non-metastatic muscle-invasive bladder cancer (MIBC) recommend neoadjuvant chemotherapy (NAC), which, however, is underutilized in practice. We hypothesized that the absence of circulating tumour cells (CTCs), an established prognostic marker in MIBC, may identify patients with such a favourable prognosis that NAC may be withheld. Methods: The CirGuidance study included adults with clinical stage T2-T4aN0-N1M0 muscle-invasive urothelial carcinoma of the bladder who were fit to undergo radical cystectomy. CTCs were enumerated using the CellSearch system. CTC-negative patients (no CTCs detectable) underwent radical surgery without NAC; CTC-positive patients (\u22651 detectable CTCs) were advised to receive NAC followed by radical surgery, but NAC could be withheld at the discretion of the treating physician. The primary endpoint was the two-year overall survival (OS) in the CTC-negative group, analysed in the intention-to-treat population. The prespecified criterion for trial success was a two-year OS of minimally 75% (95% confidence interval (CI) \u00b15%) in the CTC-negative group. Results: Of 315 patients screened for eligibility, 273 were enrolled in the study. The median age was 69 years; the median follow-up was 36 months. The two-year OS in the CTC-negative group was 69.5% (n = 203; 95% CI 62.6%-75.5%); in the CTC-positive group it was 58.2% (n = 70; 95% CI 45.5%-68.9%). CTC-positive patients had a higher rate of cancer-related mortality (hazard ratio (HR) 1.61, 95% CI 1.05-2.45, p = 0.03) and disease relapse (HR 1.87, 95% CI 1.28-2.73, p = 0.001) than CTC-negative patients. Explorative analyses suggested that CTC-positive patients who had received NAC (n = 22) survived longer than CTC-positive patients who had not (n = 48), with a two-year OS of 74.8% (95%CI 49.5%-88.8%) versus 52.0% (95% CI 37.2%-65.0%), respectively. Conclusions: The two-year OS in the CTC-negative group did not meet the prespecified criterion for trial success. However, given the trial population\u2019s advanced age and high rate of non-cancer related mortality, the benefit of NAC is likely to be limited in CTC-negative MIBC patients. CTC enumeration at the moment of diagnosis could aid in the decision to prescribe neoadjuvant chemotherapy for a muscle-invasive bladder cancer patient as a criterion in addition to clinical characteristics. Clinical trial information: NL3954. <\/jats:p>","DOI":"10.1200\/jco.2021.39.15_suppl.4523","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T14:15:18Z","timestamp":1622643318000},"page":"4523-4523","update-policy":"http:\/\/dx.doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Circulating tumor cell-driven use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer."],"prefix":"10.1200","volume":"39","author":[{"given":"Nick","family":"Beije","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingeborg Elisabeth","family":"de Kruijff","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joep","family":"de Jong","sequence":"additional","affiliation":[{"name":"Erasmus MC Cancer Institute, Rotterdam, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sjoerd O.","family":"Klaver","sequence":"additional","affiliation":[{"name":"Maasstad Ziekenhuis, Rotterdam, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"de Vries","sequence":"additional","affiliation":[{"name":"Zuyderland MC, Heerlen, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rens","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Zuyderland MC, Heerlen, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diederik Meindert","family":"Somford","sequence":"additional","affiliation":[{"name":"Canisius-Wilhelmina Ziekenhuis, Nijmegen, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ed","family":"te Slaa","sequence":"additional","affiliation":[{"name":"Isala Hospital, Zwolle, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toine","family":"van der Heijden","sequence":"additional","affiliation":[{"name":"Radboud University Medical Centre, Nijmegen, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes Alfred","family":"Witjes","sequence":"additional","affiliation":[{"name":"Department of Urology, Radboud University, Nijmegen, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Fossion","sequence":"additional","affiliation":[{"name":"Maxima MC, Eindhoven, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egbert","family":"Boeve","sequence":"additional","affiliation":[{"name":"Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"van der Hoeven","sequence":"additional","affiliation":[{"name":"Reinier de Graaf Gasthuis, Delft, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harm H.E.","family":"van Melick","sequence":"additional","affiliation":[{"name":"Sint Antonius Ziekenhuis, Nieuwegein, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl J","family":"Wijburg","sequence":"additional","affiliation":[{"name":"Department of Urology, Robotic Surgery, Rijnstate Hospital, Arnhem, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.M.","family":"Martens","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"De Wit","sequence":"additional","affiliation":[{"name":"Erasmus MC Cancer Institute, Rotterdam, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaco","family":"Kraan","sequence":"additional","affiliation":[{"name":"Erasmus MC Cancer Institute, Department of Medical Oncology and Cancer Genomics Netherlands, Rotterdam, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sleijfer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost L.","family":"Boormans","sequence":"additional","affiliation":[{"name":"Erasmus University Medical Center, Rotterdam, Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","deposited":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T14:17:49Z","timestamp":1622643469000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2021.39.15_suppl.4523"}},"issued":{"date-parts":[[2021,5,20]]},"references-count":0,"journal-issue":{"issue":"15_suppl","published-print":{"date-parts":[[2021,5,20]]}},"alternative-id":["10.1200\/JCO.2021.39.15_suppl.4523"],"URL":"https:\/\/doi.org\/10.1200\/jco.2021.39.15_suppl.4523","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2021,5,20]]},"assertion":[{"value":"2021-05-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]},{"indexed":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T16:38:12Z","timestamp":1724949492096},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"15_suppl","funder":[{"name":"None"}],"content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2021,5,20]]},"abstract":" e22526 <\/jats:p> Background: NCCN has recommended universal genetic testing of pancreatic cancer. Liquid biopsies have been approved by the FDA to facilitate detection of targetable mutations in various solid tumors. Methods: To investigate how oncologists follow NCCN guidelines and utilize liquid biopsies in pancreatic cancer, we retrospectively queried patient records from 7\/2016 to 6\/2020 in our institutional system. Those retrieved but with pancreatic cancer care from other 2 local institutions are also included. Demographics, cancer stage on diagnosis, year of diagnosis, molecular profiling (MP) and treatment setting (community vs academic) are recorded and analyzed. Results: A total of 500 pancreatic cancer patient records were identified. Of these, 234 patients were excluded due to incomplete records. Among the remaining 266 patients, 113 (42.5%) had MP performed. Younger patients and those treated at an academic setting were more likely to have MP (P= 0.0051 and 0.0010 respectively). The trend of increased utilization of MP over the years is also statistically significant (p< 0.0001). Gender, ethnicity or stage on diagnosis are not statistically significant between groups. (Table). Conclusions: MP is being increasingly utilized. However, more awareness is needed among oncologists, especially those who practice in the community setting.[Table: see text] <\/jats:p>","DOI":"10.1200\/jco.2021.39.15_suppl.e22526","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T15:11:41Z","timestamp":1622646701000},"page":"e22526-e22526","update-policy":"http:\/\/dx.doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Real-world experience of pancreatic cancer molecular profiling in a tertiary center."],"prefix":"10.1200","volume":"39","author":[{"given":"Kai","family":"Sun","sequence":"first","affiliation":[{"name":"Houston Methodist Cancer Center, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charisma","family":"Mylavarapu","sequence":"additional","affiliation":[{"name":"Houston Methodist Hospital, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aubrey","family":"Crenshaw","sequence":"additional","affiliation":[{"name":"Houston Methodist Hospital, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Houston Methodist Hospital, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enshuo","family":"Hsu","sequence":"additional","affiliation":[{"name":"Houston Methodist Research Institute, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqiong","family":"Xu","sequence":"additional","affiliation":[{"name":"Houston Methodist Research Institute, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn","family":"Niravath","sequence":"additional","affiliation":[{"name":"Houston Methodist Research Institute, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Nicolas","sequence":"additional","affiliation":[{"name":"Houston Methodist Research Institute, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Jones","sequence":"additional","affiliation":[{"name":"Houston Methodist Research Institute, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maen","family":"Abdelrahim","sequence":"additional","affiliation":[{"name":"Cockrell Center of Advanced Therapeutics Phase I Program, Houston Methodist Research Institute, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","deposited":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T15:22:51Z","timestamp":1622647371000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2021.39.15_suppl.e22526"}},"issued":{"date-parts":[[2021,5,20]]},"references-count":0,"journal-issue":{"issue":"15_suppl","published-print":{"date-parts":[[2021,5,20]]}},"alternative-id":["10.1200\/JCO.2021.39.15_suppl.e22526"],"URL":"https:\/\/doi.org\/10.1200\/jco.2021.39.15_suppl.e22526","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2021,5,20]]},"assertion":[{"value":"2021-05-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]},{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T03:00:47Z","timestamp":1716001247861},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"15_suppl","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2012,5,20]]},"abstract":" 10062 <\/jats:p> Background: Trabectedin (T) is a marine-derived alkaloid used to treat advanced soft tissue sarcomas (STS) after ifosfamide and\/or anthracyclins failure. Since then, the FSG evaluated the clinical benefit in re-administrating T after an initial hold, either medically indicated or upon patient\u2019s request. Methods: Following an online request, clinical and histopathological data were collected from six centers of the FSG who declared to have rechallenged patients. Baseline data were collected and analyze will be used. Results: From 1999 to 2011, 49 pts with T drug holiday have been identified (26 male\/ 23 female), with a median age of 50 y [23-75]. Most frequent histotypes were: myxoid liposarcoma (18, 36.7%), leiomyosarcomas (13, 26.5 %) and well-differentiated\/dedifferentiated liposarcoma (9, 18%). WHO grade were 1 in 14 (29%), 2 in 19 (39%) and 3 in 5 (10%) pts respectively. Patients who had a maximum of 2, 3 or 4 therapeutic sequences (TS) with T (drug-holiday and rechallenge) were 41\/49 ,7\/49 and 1\/49 respectively. Median number of cycles for 1, 2, 3 and 4 TS were 7 [3-21], 6 [2-30], 6 [2-9] and 6. Median total number of cycles was 15 [6-43]. Median duration of drug-holiday for 1, 2 and 3 TS were 11 [3-91], 7 [2-29] and 4 months [1-5]. Grade 3-4 toxicities incidence decreased with the number of TS (occurred in 36%, 29%, 14% and 0% of pts with 1, 2, 3 and 4 TS) as well as mean T dose per cycle (1.3 mg\/m\u00b2, 1.2 mg\/m\u00b2, 1.1 mg\/m\u00b2 and 1.1 mg\/m\u00b2 for TS 1, 2, 3, 4). Efficacy decreased with number of TS (Number of CR\/PR\/SD\/PD were 1 (2%)\/15 (31%)\/33 (67%)\/0 for TS1; 0\/4 (8%)\/29 (59%)\/16 (3%) for TS2; 0\/1 (14%)\/2 (29%)\/4 (57%) for TS3 and 0\/0\/0\/1(100%) for TS4). Median overall survival was 5.0 y [2.7-7.3] since T introduction, and 1.5 y [0.1-4.8], 0.8 y [0.5-1.3] and 0.6 y following 2nd<\/jats:sup>, 3rd<\/jats:sup> and 4th<\/jats:sup> T reintroduction respectively. Objective response after TS2 were seen in 4 cases of grade 1 sarcomas. Conclusions: Due to the lack of cumulative toxicities over time with T, its rechallenging in responding patients to T (no progression under T) have to be considered in advanced STS. <\/jats:p>","DOI":"10.1200\/jco.2012.30.15_suppl.10062","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T19:25:38Z","timestamp":1583954738000},"page":"10062-10062","source":"Crossref","is-referenced-by-count":6,"title":["Rechallenge with trabectedin in patients with locally advanced or metastatic soft tissue sarcoma\u00a0following drug holiday: The experience of the French Sarcoma Group (FSG)."],"prefix":"10.1200","volume":"30","author":[{"given":"Esma","family":"Saada","sequence":"first","affiliation":[{"name":"Centre Antoine Lacassagne, Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chahineze","family":"Rahal","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Ray Coquard","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[{"name":"Institut Bergoni\u00e9, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Chevreau","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Isambert","sequence":"additional","affiliation":[{"name":"Centre Georges Fran\u00e7ois Leclerc, Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binh","family":"Bui","sequence":"additional","affiliation":[{"name":"Institut Bergonie, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia","family":"Cassar","sequence":"additional","affiliation":[{"name":"Quintiles, Levallois-Perret, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Desmoulins","sequence":"additional","affiliation":[{"name":"Centre Georges Fran\u00e7ois Leclerc, Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Le Cesne","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[{"name":"University Claude Bernard Lyon I, Centre L\u00e9on B\u00e9rard, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Thyss","sequence":"additional","affiliation":[{"name":"Medical Oncology, Centre Antoine-Lacassagne, Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","deposited":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T19:31:30Z","timestamp":1583955090000},"score":0.0,"resource":{"primary":{"URL":"http:\/\/ascopubs.org\/doi\/10.1200\/jco.2012.30.15_suppl.10062"}},"issued":{"date-parts":[[2012,5,20]]},"references-count":0,"journal-issue":{"issue":"15_suppl","published-print":{"date-parts":[[2012,5,20]]}},"alternative-id":["10.1200\/jco.2012.30.15_suppl.10062"],"URL":"https:\/\/doi.org\/10.1200\/jco.2012.30.15_suppl.10062","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2012,5,20]]}},{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T19:15:41Z","timestamp":1720379741121},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"15_suppl","funder":[{"name":"None"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2020,5,20]]},"abstract":" e15170 <\/jats:p> Background: Tumor mutational burden (TMB) is an impressive predictive biomarker for immune checkpoint inhibitors therapy, and immunotherapy is one of the most promising methods for cancer treatment. However, the profile of TMB in various types of cancers was still poorly understood. Methods: In this study, genomic profiling of DNA was performed using next generation sequencing from a 539 genes panel in tumor tissues. The TMB was defined as the numbers of SNVs including synonymous and nonsynonymous mutations, and InDels per megabase in coding regions of sequenced genome. TMB-H was defined as highest mutation load quintile (top 20%) in each cancer type. The values of TMB of 874 patients were compared among eight main tumor types including 174 patients with liver cancer, 32 patients with bile duct cancer, 54 patients with gastric cancer, 119 patients with colorectal cancer, 27 patients with pancreatic cancer, 32 patients with melanoma, 25 patients with glioma and 411 patients with lung cancer cases by multiple independent samples nonparametric Kruskal-Wallis H test via SPSS v22.0. Results: The median values of TMB in liver cancer, bile duct cancer, gastric cancer, colorectal cancer, pancreatic cancer, melanoma, glioma and lung cancer were 10.29, 8.09, 11.03, 10.29, 5.88, 7.35, 5.88 and 7.35 Muts\/Mb, respectively. The cut-off values of TMB-H in corresponding eight solid tumors were 16.18, 19.12, 19.85, 16.18, 10.29, 13.24, 10.29 and 18.38 Muts\/Mb, respectively. Based on nonparametric Kruskal-Wallis H test, there were significant differences of median TMB values across eight independent tumor types (\u03c72<\/jats:sup> = 26.752, p = 3.693\u00d710\u22124<\/jats:sup>). Significant differences between patients with colorectal cancer and pancreatic cancer ( p = 0.005) or lung cancer ( p = 0.011) were observed via pairwise comparisons. Conclusions: Our study proved the presence of significant differences across eight cancer types, deepened the knowledge of the cancer-specific of TMB, provided useful information in immunology therapy for East Asian patients with solid tumors. As a retrospective study with a relatively small population, the conclusions of this study needed to be verified with a larger sample. <\/jats:p>","DOI":"10.1200\/jco.2020.38.15_suppl.e15170","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T15:23:11Z","timestamp":1590420191000},"page":"e15170-e15170","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of tumor mutational burden across eight types of human cancer."],"prefix":"10.1200","volume":"38","author":[{"given":"Peng","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuicui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoting","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minhui","family":"Ge","sequence":"additional","affiliation":[{"name":"Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Qin","sequence":"additional","affiliation":[{"name":"Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","deposited":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T15:29:10Z","timestamp":1590420550000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2020.38.15_suppl.e15170"}},"issued":{"date-parts":[[2020,5,20]]},"references-count":0,"journal-issue":{"issue":"15_suppl","published-print":{"date-parts":[[2020,5,20]]}},"alternative-id":["10.1200\/JCO.2020.38.15_suppl.e15170"],"URL":"https:\/\/doi.org\/10.1200\/jco.2020.38.15_suppl.e15170","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2020,5,20]]}},{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T14:07:12Z","timestamp":1649081232931},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"15_suppl","funder":[{"name":"None"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2020,5,20]]},"abstract":" 9534 <\/jats:p> Background: Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer (NSCLC). Genomic instability, defined as genome-wide copy number alterations, is a key pathogenic signature which occurs at the early stage of most cancers and is associated with an increased risk of recurrence or death. We examined the pattern of genomic instability in primary and metastatic LUAD. Methods: We performed deep targeted sequencing (425 genes) of 3395 tissue samples and whole exome sequencing (WES) of 60 tissue samples from LUAD patients. Whole-genome doubling (WGD) and arm level aneuploidy were analyzed to uncover correlation with clinical phenotypes and other genomic alterations including driver mutations, tumor mutation burden (TMB), and microsatellite instability (MSI). Results: Overall, targeted sequencing revealed that WGD occurred in 64.33% LUAD samples, which was comparable with WES results. Compared to primary site, metastasis exhibited higher proportion of WGD (1.14 fold). Specifically, liver metastasis has the highest WGD percentage among metastasis sites (~87.5%; 1.40 fold increase compared to primary). Interestingly, patients who received tyrosine kinase inhibitors (TKI) had higher frequency of WGD than patients without TKI treatment. In addition, TMB was higher in WGD+<\/jats:sup> patients but MSI status was not significantly different between groups. Arm-level aneuploidy was prevalent in this cohort. The most common amplification events were 7p gain (62%), 5p gain (54%), and 8q gain (53%); top deletion events were 19p loss (47%), 15q loss (42%), and 10 q loss (41%). Patients with EGFR or TP53 mutation were more likely to have aneuploidy compared to wildtypes. Subgroup analysis showed distinct patterns of aneuploidy among metastasis sites, suggesting organ-specific alterations. Evolution analysis showed 7p gain was an early event common in primary tumor whereas metastatic tumor had multiple distinct evolutionary trajectories following 7p gain. Several copy number signatures were associated with specific TKI and chemotherapies. For example, TKI-na\u00efve tumors lacked 7p gain but had 19p loss as the most common alteration. Conclusions: The genomic landscape of LUAD was characterized by widespread large-scale copy number alterations including WGD and chromosomal aneuploidy. Metastasis had elevated level of aneuploidy compared to primary tumors which were specific to metastatic site. Copy number signature associated with different treatments may contribute to distinct long-term survival and side effects among patients. <\/jats:p>","DOI":"10.1200\/jco.2020.38.15_suppl.9534","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T15:40:37Z","timestamp":1590421237000},"page":"9534-9534","source":"Crossref","is-referenced-by-count":1,"title":["Distinct genomic instability landscape of lung adenocarcinoma associated with treatment and metastasis."],"prefix":"10.1200","volume":"38","author":[{"given":"Chuanxin","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Cancer hospitaI of Guangzhou Medical University, Guangzhou, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, First Affiliated Hospital of Kunming Medical University, Kunming, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Bao","sequence":"additional","affiliation":[{"name":"Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ao","family":"Wang","sequence":"additional","affiliation":[{"name":"Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuang","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Kunming Medical University, Kunming, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Shen","sequence":"additional","affiliation":[{"name":"Nanjing Geneseeq Technology Inc., Nanjing, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyu","family":"Wu","sequence":"additional","affiliation":[{"name":"Nanjing Geneseeq Technology Inc., Nanjing, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Wu","sequence":"additional","affiliation":[{"name":"Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Shao","sequence":"additional","affiliation":[{"name":"Nanjing Geneseeq Technology Inc., Nanjing, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical oncology, Jiangsu Cancer Hospatal, Nanjing, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","deposited":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T15:49:18Z","timestamp":1590421758000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2020.38.15_suppl.9534"}},"issued":{"date-parts":[[2020,5,20]]},"references-count":0,"journal-issue":{"issue":"15_suppl","published-print":{"date-parts":[[2020,5,20]]}},"alternative-id":["10.1200\/JCO.2020.38.15_suppl.9534"],"URL":"https:\/\/doi.org\/10.1200\/jco.2020.38.15_suppl.9534","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2020,5,20]]}},{"indexed":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T11:13:21Z","timestamp":1653822801822},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"29_suppl","funder":[{"name":"None."}],"content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2020,10,10]]},"abstract":" 22 <\/jats:p> Background: End-of-life anti-neoplastic treatment does not improve quality of life nor prolong survival of advanced cancer patients. It is also not cost-effective. To-date, there has been little data examining real-world patterns of chemotherapy and immunotherapy treatment at end of life. We investigated use of chemotherapy and\/or immunotherapy in the last 14 days of life across a community oncology network of 5 practices, 100 sites of care, and 160 oncology providers. Methods: Using a real-time, network-wide database, we identified patients with solid tumor malignancies who died during an episode of active treatment, defined as having received intravenous (IV) chemotherapy and\/or immunotherapy within 90 days of death. We then identified patients in this cohort who received IV chemotherapy and\/or IV immunotherapy within 14 days of death (TxEoL). We studied TxEoL patterns by cancer type, treatment type, line of therapy, patient age, patient race, and oncology provider years in practice. Statistical significance was assessed using Pearson\u2019s Chi-squared test. Results: 2,858 qualifying solid tumor cancer patients with dates of death between 1\/1\/2019 and 5\/31\/2020 were identified. Observed rates of TxEoL were 16.7% for immunotherapy alone vs. 19.6% for chemotherapy +\/- immunotherapy (p = 0.09). We found high variation in TxEoL across 132 oncologists that had 5 or more deceased patients (range: 0% to 50%, mean: 19.2%, median: 19.6%). We found no association of TxEOL with physician years in practice, patient age or race. Rates of TxEoL in the first-line setting were significantly higher than in second-line setting or later (23.3% versus 16.4%, p < 0.01). Patients with head and neck, pancreatic, and hepatobiliary malignancies were the most likely to receive TxEoL, while patients with prostate, brain, and ovarian malignancies were the least likely to receive TxEoL. Conclusions: Our data and method identified wide variation in TxEoL patterns across a large community oncology network, suggesting room for provider-level interventions to improve treatment decisions in patients at high risk of death. Studies within our group, such as examining the impact of palliative care referrals on IV anti-cancer treatment in patients potentially facing end of life, are ongoing. <\/jats:p>","DOI":"10.1200\/jco.2020.38.29_suppl.22","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T13:35:56Z","timestamp":1602164156000},"page":"22-22","update-policy":"http:\/\/dx.doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Real-world patterns of chemotherapy and immunotherapy utilization at end of life in a large community oncology network."],"prefix":"10.1200","volume":"38","author":[{"given":"Stephen Matthew","family":"Schleicher","sequence":"first","affiliation":[{"name":"Tennessee Oncology, Nashville, TN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garrett","family":"Young","sequence":"additional","affiliation":[{"name":"OneOncology, Nashville, TN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Arrowsmith","sequence":"additional","affiliation":[{"name":"Tennessee Oncology, Nashville, TN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl A.","family":"Prince","sequence":"additional","affiliation":[{"name":"West Cancer Center, Memphis, TN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn Kay","family":"Winters","sequence":"additional","affiliation":[{"name":"New York Cancer and Blood Specialists, Port Jefferson Station, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron J.","family":"Lyss","sequence":"additional","affiliation":[{"name":"Tennessee Oncology, Nashville, TN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Waynick","sequence":"additional","affiliation":[{"name":"Tennessee Oncology, Nashville, TN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandhya","family":"Mudumbi","sequence":"additional","affiliation":[{"name":"Tennessee Oncology, Nashville, TN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duncan","family":"Allen","sequence":"additional","affiliation":[{"name":"OneOncology, Nashville, TN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie R.","family":"Dickson","sequence":"additional","affiliation":[{"name":"Tennessee Oncology, Nashville, TN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee S.","family":"Schwartzberg","sequence":"additional","affiliation":[{"name":"West Cancer Center, Memphis, TN;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T10:36:07Z","timestamp":1653820567000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2020.38.29_suppl.22"}},"issued":{"date-parts":[[2020,10,10]]},"references-count":0,"journal-issue":{"issue":"29_suppl","published-print":{"date-parts":[[2020,10,10]]}},"alternative-id":["10.1200\/JCO.2020.38.29_suppl.22"],"URL":"https:\/\/doi.org\/10.1200\/jco.2020.38.29_suppl.22","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2020,10,10]]},"assertion":[{"value":"2020-10-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]},{"indexed":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T10:41:35Z","timestamp":1653820895324},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4_suppl","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2018,2,1]]},"abstract":" 422 <\/jats:p> Background: In the era of parenchymal sparing surgery, detecting more colorectal liver metastases (CRLM) is essential to optimize the treatment. We evaluated the added-value of contrast enhanced intraoperative ultrasound (CE-IOUS) with a prospective design. Methods: We used an optimal 2-stage Simon\u2019s design for this two-center study open for patients with operable CRLMs. Primary objective was the justified clinical utility of contrast-enhanced IOUS. Secondary objectives included detection rate of CRLMs, characterization rate of focal liver lesions, specific toxicity and detection of missing CRLMs. Results: Among the 58 eligible patients, 54 were eligible and assessable. Of these 54 patients, 36 were men (66.7%), median age was 63.6 years (range, 37-81), and 43 patients underwent pre-operative chemotherapy. The median number of CRLMs was 2 (range, 1-11). Pre-operative staging was performed using MRI in all 58 eligible patients, CT scan in 41 (70%) and PET-scan in 21 (36%). Compared to pre-operative staging, IOUS allowed identification of 40 new CRLMs in 11 (20.4%) patients. Furthermore, compared to IOUS, CE-IOUS allowed identification of 9 additional CRLMs in 8 (14.8%) patients. The correct detection rate based on pathological exams was 0.94. No additional missing CRLM was diagnosed. The surgical procedure was altered in 5 (9.26%) patients but was justified only in 4 patients (one lesion was ablated without previous biopsy), leading to a clinical utility rate of 7.70% (95 CI, [3.2, 18.6]). There was no specific toxicity reported. Conclusions: Despite the primary endpoint not met for one protocol violation,the Uliis study demonstrates an added-value for CE-IOUS for surgeons treating CRLMs, especially for advanced cases pre-treated by chemotherapy. Clinical trial information: NCT01880554. <\/jats:p>","DOI":"10.1200\/jco.2018.36.4_suppl.422","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T15:19:35Z","timestamp":1546442375000},"page":"422-422","update-policy":"http:\/\/dx.doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Contrast-enhanced intra-operative ultrasound as a clinical decision making tool during surgery for colorectal liver metastases: The ULIIS study."],"prefix":"10.1200","volume":"36","author":[{"given":"Serge","family":"Evrard","sequence":"first","affiliation":[{"name":"Institut Bergoni\u00e9, Bordeaux, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e9goire","family":"D\u00e9solneux","sequence":"additional","affiliation":[{"name":"Institut Bergoni\u00e9, Bordeaux, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milene","family":"Isambert","sequence":"additional","affiliation":[{"name":"Institut Bergoni\u00e9, Bordeaux, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Mathoulin-P\u00e9lissier","sequence":"additional","affiliation":[{"name":"Institut Bergoni\u00e9, Comprehensive Cancer Centre, Bordeaux, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lien","family":"Dupr\u00e9","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard, Lyon, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Rivoire","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard, Lyon, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Catena","sequence":"additional","affiliation":[{"name":"Institut Bergoni\u00e9, Bordeaux, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Palussi\u00e8re","sequence":"additional","affiliation":[{"name":"Institut Bergoni\u00e9, Bordeaux, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Dinart","sequence":"additional","affiliation":[{"name":"Institut Bergoni\u00e9, Bordeaux, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carine A.","family":"Bellera","sequence":"additional","affiliation":[{"name":"Institut Bergoni\u00e9, Comprehensive Cancer Centre, Bordeaux, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","link":[{"URL":"http:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2018.36.4_suppl.422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T10:11:43Z","timestamp":1653819103000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2018.36.4_suppl.422"}},"issued":{"date-parts":[[2018,2,1]]},"references-count":0,"journal-issue":{"issue":"4_suppl","published-print":{"date-parts":[[2018,2,1]]}},"alternative-id":["10.1200\/JCO.2018.36.4_suppl.422"],"URL":"https:\/\/doi.org\/10.1200\/jco.2018.36.4_suppl.422","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2018,2,1]]},"assertion":[{"value":"2018-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]},{"indexed":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T10:41:39Z","timestamp":1653820899430},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4_suppl","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2018,2,1]]},"abstract":" 663 <\/jats:p> Background: Nucleotide excision repair (NER) is known as part of the DNA damage response (DDR) against platinum-induced DNA damage. Polymorphisms in miRNA binding sites of replication protein A ( RPA2) and General Transcription Factor IIH Subunit 1 ( GTF2H1) genes in NER pathway have shown to correlate with colorectal cancer risk. We tested whether the NER-related single nucleotide polymorphisms (SNPs) predict oxaliplatin efficacy in FOLFOXIRI regimen in patients (pts) with metastatic colorectal cancer (mCRC). Methods: Genomic DNA was extracted from 457 blood samples of mCRC pts enrolled in the TRIBE trial: 230 pts received first-line (1L) FOLFOXIRI plus bevacizumab (discovery cohort: median age, 60 yrs; median follow-up, 46.6 mos); and 227 pts received 1L FOLFIRI plus bevacizumab (control cohort: median age, 60 yrs; median follow-up, 49.0 mos). SNPs were analyzed by PCR-based direct sequencing. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier curves, log-rank test, and Cox proportional hazards regression. Results: In KRAS wild-type population among the discovery cohort, the C\/C variant in RPA2 rs7356 was associated with shorter PFS and OS than any T allele (9.1 vs 13.3 mos, HR 2.32, 95%CI: 1.07-5.03, P= 0.020; 20.8 vs 37.1 mos, HR 1.94, 95%CI: 0.94-3.99, P= 0.059). Any C allele in GTF2H1 rs4596 was associated with shorter PFS than the G\/G variant (10.8 vs 13.3 mos, HR1.64, 95%CI: 0.95-2.81, P= 0.045). In multivariable analysis, RPA2 rs7356 remained significant for PFS and OS (HR 2.97, 95%CI: 1.27-6.94, P= 0.012; HR 2.58, 95%CI: 1.19-5.58, P= 0.016). In all population of the discovery cohort, pts with any GTF2H1 rs4596 C allele had remarkably shorter PFS and OS than those with the G\/G variant (11.3 vs 13.2 mos, HR 1.32, P= 0.087; 28.6 vs 34.3 mos, HR 1.36, P= 0.076). The findings remained in multivariable analysis. These findings were not confirmed in the control cohort. Conclusions: We suggest that miRNA binding sites of NER-related genes regulate DDR for oxaliplatin-related DNA damage. Germline RPA2 and GTF2H1 polymorphisms may predict oxaliplatin efficacy in mCRC pts. <\/jats:p>","DOI":"10.1200\/jco.2018.36.4_suppl.663","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T15:19:35Z","timestamp":1546442375000},"page":"663-663","update-policy":"http:\/\/dx.doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Single nucleotide polymorphisms in miRNA binding sites of nucleotide excision repair-related genes to predict clinical benefit of oxaliplatin in FOLFOXIRI plus bevacizumab in TRIBE trial."],"prefix":"10.1200","volume":"36","author":[{"given":"Mitsukuni","family":"Suenaga","sequence":"first","affiliation":[{"name":"USC Keck School of Medicine Norris Comprehensive Cancer Center, Los Angeles, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Schirripa","sequence":"additional","affiliation":[{"name":"USC Keck School of Medicine Norris Comprehensive Cancer Center, Los Angeles, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Cao","sequence":"additional","affiliation":[{"name":"USC Keck School of Medicine, Los Angeles, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu","family":"Zhang","sequence":"additional","affiliation":[{"name":"USC Keck School of Medicine, Los Angeles, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyun","family":"Yang","sequence":"additional","affiliation":[{"name":"USC Keck School of Medicine Norris Comprehensive Cancer Center, Los Angeles, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[{"name":"Pisa University Hospital, Tuscan Tumor Institute, Pisa, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Murgioni","sequence":"additional","affiliation":[{"name":"Istituto Oncologico Veneto, IRCCS, Padova, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[{"name":"Istituto Oncologico Veneto, IRCCS, Padova, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Ning","sequence":"additional","affiliation":[{"name":"USC Keck School of Medicine Norris Comprehensive Cancer Center, Los Angeles, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Okazaki","sequence":"additional","affiliation":[{"name":"USC Keck School of Medicine Norris Comprehensive Cancer Center, Los Angeles, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin D","family":"Berger","sequence":"additional","affiliation":[{"name":"USC Keck School of Medicine, Los Angeles, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"USC Keck School of Medicine Norris Comprehensive Cancer Center, Los Angeles, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roel","family":"Gopez","sequence":"additional","affiliation":[{"name":"USC Keck School of Medicine Norris Comprehensive Cancer Center, Los Angeles, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afsaneh","family":"Barzi","sequence":"additional","affiliation":[{"name":"USC Keck School of Medicine Norris Comprehensive Cancer Center, Los Angeles, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fotios","family":"Loupakis","sequence":"additional","affiliation":[{"name":"Istituto Toscano Tumori, Pisa, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Falcone","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz-Josef","family":"Lenz","sequence":"additional","affiliation":[{"name":"USC Keck School of Medicine, Los Angeles, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","link":[{"URL":"http:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2018.36.4_suppl.663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T10:16:53Z","timestamp":1653819413000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2018.36.4_suppl.663"}},"issued":{"date-parts":[[2018,2,1]]},"references-count":0,"journal-issue":{"issue":"4_suppl","published-print":{"date-parts":[[2018,2,1]]}},"alternative-id":["10.1200\/JCO.2018.36.4_suppl.663"],"URL":"https:\/\/doi.org\/10.1200\/jco.2018.36.4_suppl.663","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2018,2,1]]},"assertion":[{"value":"2018-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]},{"indexed":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T11:41:09Z","timestamp":1653824469118},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4_suppl","funder":[{"name":"None."}],"content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2022,2,1]]},"abstract":" TPS228 <\/jats:p> Background: Colorectal cancer patients with initially unresectable liver-only metastases may be cured after downsizing of metastases by conversion therapy. However, the optimal regimen of conversion therapy for RAS mutant patients has not been defined. Methods: BECOME2 is a multicenter, randomized, phase 3 clinical study. RAS mutant and BRAF wild type colorectal cancer patients with initially unresectable liver-limited metastases are eligible. The (un)resectability status is prospectively assessed by a central multidisciplinary team (MDT) consisting of at least one radiologist and three liver surgeons, according to predefined criteria. RAS and BRAF mutation status were evaluated according to primary tumor. Patients with RAS mutant and BRAF wild type will be randomized between modified FOLFOXIRI (IRI, 165mg\/m2; Oxa, 85mg\/m2; LV, 400mg\/m2; 5-FU 2400mg\/m2) plus bevacizumab (5mg\/kg) and modified FOLFOX6 (mFOLFOX6) plus bevacizumab. Radiological evaluation to assess conversion to resectability will be performed by the central MDT every eight weeks. The primary study endpoint is conversion resection rate. Secondary endpoints are the ETS, DpR, ORR, PFS, OS, toxicity, perioperative complication, and the proportion of no evidence of disease. Clinical trial information: NCT04781270. <\/jats:p>","DOI":"10.1200\/jco.2022.40.4_suppl.tps228","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T20:44:02Z","timestamp":1642625042000},"page":"TPS228-TPS228","update-policy":"http:\/\/dx.doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS mutant unresectable colorectal liver-limited metastases: A study protocol of a multicenter randomized controlled phase 3 (BECOME2) trial."],"prefix":"10.1200","volume":"40","author":[{"given":"Wentao","family":"Tang","sequence":"first","affiliation":[{"name":"Zhongshan Hospital, Fudan University, Shanghai, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Zhongshan Hospital Fudan University, Shanghai, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ren","sequence":"additional","affiliation":[{"name":"Institute of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Hai","family":"Ye","sequence":"additional","affiliation":[{"name":"Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianshu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital Fudan University, Shanghai, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T11:15:49Z","timestamp":1653822949000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2022.40.4_suppl.TPS228"}},"issued":{"date-parts":[[2022,2,1]]},"references-count":0,"journal-issue":{"issue":"4_suppl","published-print":{"date-parts":[[2022,2,1]]}},"alternative-id":["10.1200\/JCO.2022.40.4_suppl.TPS228"],"URL":"https:\/\/doi.org\/10.1200\/jco.2022.40.4_suppl.tps228","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2022,2,1]]},"assertion":[{"value":"2022-01-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]},{"indexed":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T04:10:24Z","timestamp":1653883824220},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4_suppl","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2017,2,1]]},"abstract":" 790 <\/jats:p> Background: The role of adjuvant chemotherapy (AC) after chemoradiotherapy and surgery in stage II and III of rectal cancer is not well defined. Neither the regimen nor the duration is clear. Besides, guidelines from different expert groups are conflicting. Methods: 224 patients diagnosed from January 2003 to December 2013 with rectal adenocarcinoma T3\/T4 and\/or positive node staged by ultrasound or magnetic resonance imaging was collected retrospectively from the Pathology Department data base. Results: Of the 224 patients 61.6% were male, median of age at diagnosis 68.6 years (range 31.3-85.4). All of them received 50.4 Gy with different concomitant regimens (capecitabine, continuous infusion of fluoracil or bolus of fluoracil-leucovorin). 13.4% of patients achieved a pathological complete response. 76.8% of the cohort received adjuvant chemotherapy. The main reasons for not receiving chemotherapy were ECOG \u2265 2, surgery complications and a decision of the patient. 51.2% of patients received an oxaliplatin based regimen and the median time of chemotherapy duration was 4 months (range 1-6 months). Local relapse was diagnosed in 6.3% of patients while a systemic relapse was found in 22.3%. Patients without AC had a mean overall survival (OS) of 85.5 months (CI 95% 70.7-100.4) versus 119.8 monts (CI 95% 110.8-128.8) in the AC cohort (p 0.002) without reaching the median after 58 months (range 8-153.9) median follow-up. Disease free survival (DFS) was also better in the AC cohort with a mean DFS of 104 months (CI 95% 94.3-113.6) versus 71.4 months (CI 95% 55.4-87.4), p = 0.01. Conclusions: AC after chemoradiotherapy and surgery in stage II and III rectal cancer as a standard does not exist. In our cohort, AC showed a significant improve in OS and DFS, but the limitations of a retrospective study should be considered, as well as the impact of surgery on metastasis and salvage chemotherapies. Randomized studies are clearly needed. <\/jats:p>","DOI":"10.1200\/jco.2017.35.4_suppl.790","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T17:08:11Z","timestamp":1490116091000},"page":"790-790","update-policy":"http:\/\/dx.doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Rectal adenocarcinoma: Outcomes of adjuvant chemotherapy after neoajuvant chemoradiotherapy in a retrospective cohort."],"prefix":"10.1200","volume":"35","author":[{"given":"Vanessa","family":"Pach\u00f3n Olmos","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Reguera Puertas","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reyes","family":"Ferreiro Monteagudo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FEDERICO","family":"LONGO","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Rodr\u00edguez Garrote","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Vaz Salgado","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Guillen","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Gion Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Molina CerrilloMD","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Martinez Saez","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Villamayor Delgado","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Die Trill","sequence":"additional","affiliation":[{"name":"General Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estela","family":"Tobaruela de Blas","sequence":"additional","affiliation":[{"name":"General Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Moreno Montes","sequence":"additional","affiliation":[{"name":"General Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Garc\u00eda P\u00e9rez","sequence":"additional","affiliation":[{"name":"General Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Diego","family":"Pina","sequence":"additional","affiliation":[{"name":"General Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Alejandra","family":"Caminoa-Lizarralde Aiza","sequence":"additional","affiliation":[{"name":"Pathology Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cayetano","family":"Sempere Ortega","sequence":"additional","affiliation":[{"name":"Radiology Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"L\u00f3pez-Campos","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Carrato","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"language":"en","link":[{"URL":"http:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2017.35.4_suppl.790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T08:39:39Z","timestamp":1653813579000},"score":0.0,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2017.35.4_suppl.790"}},"issued":{"date-parts":[[2017,2,1]]},"references-count":0,"journal-issue":{"issue":"4_suppl","published-print":{"date-parts":[[2017,2,1]]}},"alternative-id":["10.1200\/JCO.2017.35.4_suppl.790"],"URL":"https:\/\/doi.org\/10.1200\/jco.2017.35.4_suppl.790","ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"published":{"date-parts":[[2017,2,1]]},"assertion":[{"value":"2017-03-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}],"items-per-page":20,"query":{"start-index":0,"search-terms":null}}}